Image source: Shutterstock

Highlights

  • NUZ-001 and its metabolite effectively cross the blood-brain barrier in rodents, achieving CNS exposure levels shown to reverse TDP-43 aggregation.

  • Both compounds demonstrated consistent inhibition of TDP-43 aggregation across all tested concentrations in a repeat dose-response study.

  • Results validate therapeutic potential for treating ALS and other TDP-43 proteinopathies including FTD, AD, and LATE.

Neurizon® Therapeutics Limited (ASX:NUZ & NUZOA), a clinical-stage biotechnology company focused on treating neurodegenerative disorders, has announced new rodent pharmacokinetic (PK) data demonstrating that its lead compound NUZ-001 and its primary active metabolite, NUZ-001 Sulfone, successfully cross the blood-brain barrier (BBB). This achievement marks a significant advancement in the development of therapeutics targeting central nervous system (CNS) disorders, including Amyotrophic Lateral Sclerosis (ALS).

The data shows that CNS concentrations of both NUZ-001 and NUZ-001 Sulfone in rodent models reached levels known to reverse pathological aggregation of TAR DNA-binding protein 43 (TDP-43), a hallmark of ALS and several other neurodegenerative diseases. These results are particularly important as delivering therapeutically effective doses across the BBB remains a critical challenge in the treatment of CNS disorders.

Dose-Response Study Confirms Inhibition of TDP-43 Aggregation

In addition to the PK findings, Neurizon also reported results from a repeated TDP-43 aggregation assay using a patient-derived induced pluripotent stem cell (iPSC) neuronal model of ALS. The study was designed to expand the dose-response curve and confirmed that NUZ-001 and NUZ-001 Sulfone significantly prevented TDP-43 aggregation at all concentrations tested.

These outcomes reinforce earlier data from the company’s Phase 1 MEND study, which showed encouraging signs of efficacy for NUZ-001 in ALS patients. The convergence of brain-penetrant properties and anti-aggregation effects adds strong translational relevance to the compound’s profile.

Broader Implications for TDP-43 Proteinopathies

The capability of NUZ-001 to achieve therapeutic CNS concentrations opens potential pathways beyond ALS. The findings support its development for a range of TDP-43-associated neurodegenerative diseases, including frontotemporal dementia (FTD), Alzheimer’s disease (AD), and limbic-predominant age-related TDP-43 encephalopathy (LATE).

With these results, Neurizon advances closer to validating NUZ-001 as a first-in-class treatment directly targeting disease-driving mechanisms within the brain.